Jānis Romanovskis, Chairman of the Management Board of Grindeks JSC, points out: "Former soviet republics members of CIS are, strategically, the most important markets for final dosage forms of medicines manufactured by Grindeks, where the demand for our products, especially for Mildronate®, is increasing every year. Uzbekistan is a perspective developing market, and our new representative office will facilitate to make the most of its resources."
In 2007, export volume to Uzbekistan exceeded half a million LVL. Currently, 10 of our products are registered in Uzbekistan.
The Head of Representative Office is Mastura Kutmatova, and there are totally three employees in the Representative Office.
About JSC Grindeks
JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
A range of Grindeks's products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.
Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 92% of the total turnover. The main markets are: the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of "Riga Stock Exchange".
For further information, please visit www.grindeks.lv.